Literature DB >> 27124384

A population-based registry study evaluating surgery in newly diagnosed uterine cancer.

Christer Borgfeldt1, Grigorios Kalapotharakos1, Katrin C Asciutto1, Mats Löfgren2, Thomas Högberg3.   

Abstract

INTRODUCTION: The aim was to evaluate surgical treatment of newly diagnosed uterine cancer in a Swedish population.
MATERIAL AND METHODS: Data in the GynOp registry from 2008 to 2014 were analyzed.
RESULTS: In total, 3443 cases were included: 430 (12%) were robotic-assisted laparoscopic, 272 (8%) laparoscopic, and 2741 (80%) abdominal operations. There was an increasing trend in minimally invasive surgery from 2008 to 2014 (41%). Women with lymph nodes removed in the robotic-assisted laparoscopic group experienced less blood loss (mean 105 vs. 377 mL), shorter length of hospital stay (2.4 vs. 4.1 days), and fewer days to normal activities of daily living (6.5 vs. 12.7 days) (all p < 0.001) compared with the abdominal group, but operating time did not differ. Similar results were found in women with no lymph node removal and in women with body mass index ≥35. Major complications during hospital stay, reoperations, and time to work were less in both minimally invasive groups. More lymph nodes were retrieved in the abdominal (mean 34.4) than in the robotic-assisted laparoscopic (mean 26.0) group, but the number of women with lymph node metastases did not differ, totaling 211/960 (21.9%; 95% CI 19.4-24.7%). Isolated para-aortic lymph node metastases were found in 3.9% (95% CI 2.4-5.6%) of women.
CONCLUSIONS: Minimally invasive surgery in uterine cancer patients reduces days to normal activities of daily living, number of days to return to work, length of hospital stay, and blood loss in patients without and with lymph node dissection and in obese patients.
© 2016 Nordic Federation of Societies of Obstetrics and Gynecology.

Entities:  

Keywords:  Cancer; hysterectomy; laparoscopy; lymphadenectomy; obesity; surgical techniques; training

Mesh:

Year:  2016        PMID: 27124384     DOI: 10.1111/aogs.12918

Source DB:  PubMed          Journal:  Acta Obstet Gynecol Scand        ISSN: 0001-6349            Impact factor:   3.636


  5 in total

Review 1.  Influence of steep Trendelenburg position on postoperative complications: a systematic review and meta-analysis.

Authors:  Satoshi Katayama; Keiichiro Mori; Benjamin Pradere; Takafumi Yanagisawa; Hadi Mostafaei; Fahad Quhal; Reza Sari Motlagh; Ekaterina Laukhtina; Nico C Grossmann; Pawel Rajwa; Abdulmajeed Aydh; Frederik König; Pierre I Karakiewicz; Motoo Araki; Yasutomo Nasu; Shahrokh F Shariat
Journal:  J Robot Surg       Date:  2021-12-31

Review 2.  Robot-assisted hysterectomy for endometrial and cervical cancers: a systematic review.

Authors:  Immaculate F Nevis; Bahareh Vali; Caroline Higgins; Irfan Dhalla; David Urbach; Marcus Q Bernardini
Journal:  J Robot Surg       Date:  2016-07-16

3.  Cervical invasion, lymphovascular space invasion, and ovarian metastasis as predictors of lymph node metastasis and poor outcome on stages I to III endometrial cancers: a single-center retrospective study.

Authors:  Min Li; Shuwei Wu; Yangqin Xie; Xiaohui Zhang; Zhanyu Wang; Ying Zhu; Shijie Yan
Journal:  World J Surg Oncol       Date:  2019-11-16       Impact factor: 2.754

4.  Survival in endometrial cancer in relation to minimally invasive surgery or open surgery - a Swedish Gynecologic Cancer Group (SweGCG) study.

Authors:  Christer Borgfeldt; Erik Holmberg; Janusz Marcickiewicz; Karin Stålberg; Bengt Tholander; Elisabeth Åvall Lundqvist; Angelique Flöter-Rådestad; Maria Bjurberg; Pernilla Dahm-Kähler; Kristina Hellman; Elisabet Hjerpe; Preben Kjölhede; Per Rosenberg; Thomas Högberg
Journal:  BMC Cancer       Date:  2021-06-02       Impact factor: 4.430

Review 5.  A comparison of operative outcomes between standard and robotic laparoscopic surgery for endometrial cancer: A systematic review and meta-analysis.

Authors:  Thomas Ind; Alex Laios; Matthew Hacking; Marielle Nobbenhuis
Journal:  Int J Med Robot       Date:  2017-08-01       Impact factor: 2.547

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.